Board of Jubilant Pharma approves proposal to launch unsecured high yield bonds issue
Jubilant Life Sciences announced that the Board of Directors of Company's material wholly-owned subsidiary, Jubilant Pharma (JPL) has, at its meeting held on 23 September 2016, approved the proposal to launch a benchmark offering of unsecured high yield bonds (the Notes) outside India by JPL, under Regulation S of the US Securities Act. The Notes are proposed to be listed on the Singapore Exchange Securities Trading.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
